Recent research led by Shiyi Yu, MD, has identified five key blood proteins that can predict the onset of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) up to 16 years before symptoms manifest. In the first-of-its-kind study, researchers combed through data from 52,952 UK Biobank participants. The movement as a whole reflects monumental progress made in the field of early detection and intervention tactics for this troublesome condition. Those results have the potential to make a big impact in how frontline medical providers screen for MASLD. This disease is further associated with severe health outcomes, such as cardiovascular disease.
The study followed people who did not have MASLD at baseline. They were tracked for an impressive average of 16.6 years. What these researchers found was that changes in plasma levels of these proteins corresponded to an increased 33-fold risk of developing MASLD. Greater baseline levels of these proteins greatly amplified the risk. In reality, this correlation led to an almost tenfold increase, with hazard ratios between 7.05 and 9.81.
Significance of Early Detection
Shiyi Yu, MD, stresses that at-risk patients need to be made aware of their risk of MASLD. Many don’t know that this research is aimed at raising awareness about liver disease. Most patients are unaware of their risk until they develop acute and potentially severe symptoms.
“Too often, people do not find out they are at risk for liver disease before they are diagnosed and coping with symptoms,” said Yu.
From this analysis, five proteins emerged as powerful predictive biomarkers for progression to MASLD within five years. These proteins include CDHR2, FUOM, KRT18, ACY1, and GGT1. This unusual combination achieved astounding predictive precision. The area under the curve (AUC) values were between 0.797 and 0.825.
Loren A. Laine, MD, noted the high predictive performance of this model:
“So, for this to have an accuracy up to the 90s indicates a really excellent [predictive] performance.”
Ultimately, those findings suggest that this predictive model can help set the stage for earlier intervention strategies. These approaches will involve extensive emphasis on lifestyle changes and increased monitoring.
Personalized Interventions
Herein, we discuss the discovery of these biomarkers and the opportunities presented for precisely targeted interventions that have the potential to dramatically change patient trajectories. As Shiyi Yu noted, these interventions can vary substantially, from broad lifestyle modification to targeted medical advice.
“Counseling on diet, physical activity, and other factors years before liver damage begins could potentially avert disease progression altogether,” Yu stated.
He noted the value for patients to receive an added benefit from annual elastography or ultrasound surveillance. This proactive approach removes the burden of waiting for unexpected liver function test or imaging findings. This early prevention strategy would be instrumental in recognizing those at heightened risk years before any permanent harm might set in.
“By finding at-risk patients early, we hope to help stop MASLD before it starts,” Yu added.
Loren A. Laine strongly seconded this line of thinking and stressed the possible benefits of being able to pinpoint people at higher risk. He emphasized the need to use protein-based risk assessments to engage and inspire patients. He proposed that this may be a better measure than other metrics, like BMI or liver enzymes.
Implications for Future Research
The implications of this study extend beyond individual patient care. They may influence future research directions in the field of liver disease. Rotonya Carr, MD, an advocate for use of predictive analytics in medicine, says that’s the promise of these findings. She imagines tools like those that are commonplace in cardiology.
“I see this as being akin to what cardiology has had for quite some time, where they have [cardiovascular risk] disease calculators in which patients or their physicians can enter data and then estimate their risk of developing cardiovascular disease over, for instance, 10 years,” Carr explained.
Shiyi Yu emphasized how promising these findings are to deeply change early intervention approaches. He thinks that this model is the first high-performance predictive tool for MASLD. It puts the power back in the hands of healthcare providers so they can proactively address liver health.
“This represents the first high-performance, ultra-early (16 years) predictive model for MASLD,” Yu stated.
Leave a Reply